A phase II trial opens up discussions on how to define success of chemoprevention studies

Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings

Novel approaches including the use of a JAK-STAT inhibitor, a nomogram and assessment of eosinophil proportions are presented for improving the management of immune-related adverse events 

In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy

Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed  

In the IND227 trial, more pronounced benefits of the immunotherapy were observed in patients with non-epithelioid histology and regardless of PD-L1 status 

Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment 

Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients

The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing  

However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial